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Background: Bivalirudin monotherapy provides a similar protection from ischemic heart disease while lowering the risk of bleeding complications 
in comparison to heparin plus GP IIb/IIIa blockade, especially in patients undergoing PCI. However, the efficacy and safety of bivalirudin 
monotherapy without timely thienopyridine preloading remains unclear.
Methods: Electronic searches were conducted of all published studies reporting on the efficacy and safety of bivalirudin monotherapy in 
comparison to heparin plus GP IIb/IIIa blockade along with the timing of thienopyridine loading. A meta-analysis was performed with major bleeding 
and MACE as the primary endpoints.
Results: We identified 3 studies, involving 5,117 patients published between 2003 and 2007. MACE was higher in the bivalirudin monotherapy 
group in comparison to the heparin plus GP IIb/IIIa blockade group (9.0% vs. 7.4%; OR 1.24 (95% CI 1.01 to 1.52), p=0.04 (Figure). The results 
showed no heterogeneity among the trials (Q-test: 0.41; I2: 0%; p=0.81). No publication bias was detected (Egger’s test: p=0.18). There was a trend 
toward less major bleeding in patients receiving bivalirudin monotherapy compared with those receiving heparin plus GP IIb/IIIa blockade (2.5% vs. 
4.1%; OR 0.62 (95% CI 0.35 to 1.08), p=0.09. 
Conclusion: The current meta-analysis indicates that bivalirudin monotherapy without timely thienopyridine preloading is associated with higher 
MACE rates in patients presenting with ischemic heart disease.
